Global Infliximab And Biosimilar Market Size By Geographic Scope And Forecast

Infliximab And Biosimilar Market Size And Forecast

Infliximab And Biosimilar Market size is growing at a moderate pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2022 to 2030.

The fact that numerous biological innovative products, including monoclonal antibodies (mAbs), are nearing patent expiration is a major driver for the Infliximab And Biosimilar Market. Growing research into developing biosimilars for these is a key trend that is boosting potential growth. The Global Infliximab And Biosimilar Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Infliximab And Biosimilar Market Definition

Biosimilars are biological products that are highly similar to an already FDA-approved medicine, known as the reference biological product. Biosimilars are medications that have been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and have no clinically significant changes from the reference products in terms of safety, purity, efficacy, and effectiveness. These biosimilar medications can only be approved for indications and conditions that major regulatory agencies have previously approved for the reference product. Infliximab is a monoclonal antibody developed in collaboration between Janssen Biotech Inc. and Merck & Co. (MSD) and was approved by the US Food and Drug Administration in 1998. It is used in adult and pediatric patients to treat Crohn’s disease.

Global Infliximab And Biosimilar Market Overview

The Rising incidence of autoimmune diseases, particularly in rheumatoid arthritis and plaque psoriasis, discounted pricing across the European market, and faster reaction times due to an intravenous mode of administration are all driving factors for the Remicade biosimilar. Furthermore, introducing biosimilar versions could give financial relief to healthcare systems while also improving patients’ access to essential medications. The Remicade biosimilar’s barriers include substantial adverse effects linked with drug use that could lead to hospitalization or even death in rare cases.

The rising prevalence of relevant autoimmune illnesses and reduced Remicade biosimilar pricing in European markets are projected to contribute to higher referral and consumption of the medicine. Faster approval procedures and appropriate U.S. FDA-certified manufacturing facilities in regional nodal nations are variables that contribute to increasing drug acceptance. Furthermore, differentiated nomenclature and visible labeling to enable proper prescribing and dispensing and enhanced post-marketing surveillance are variables that could contribute significantly to prescriber confidence and increased market penetration in the coming years.

Global Infliximab And Biosimilar Market Segmentation Analysis

The Global Infliximab And Biosimilar Market is Segmented on the basis of Geography.

Infliximab And Biosimilar Market, By Geography

• North America• Europe• Asia Pacific• Rest of the world

On the basis of Geography, the Global Infliximab And Biosimilar Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. Europe leads the Infliximab And Biosimilar Market, followed by Japan and Latin America. The primary reason for this is the release of the biosimilar version soon after the branded version’s patent expiration.

Key Players

The “Global Infliximab And Biosimilar Market” study report will provide a valuable insight with an emphasis on the global market. The major players in the market are Pfizer Inc. (AC. Hospira), Janssen Biotech Inc., Merck &Co., Celltrion Inc., Alvogen, Napp Pharmaceuticals, and Nippon Kayaku.

Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

Key Developments

• In Sep 2016, Pfizer Inc. announced the confirmatory study (REFLECTIONS B537-02) comparing the efficacy, safety, and immunogenicity of PF-06438179 (infliximab-Pfizer) to Remicade® (infliximab) met its primary endpoint. The proposed biosimilar PF-06438179 demonstrated equivalent efficacy to the originator product as measured by the American College of Rheumatology 20 (ACR20) response at Week 14. PF-06438179 is being developed as a Remicade biosimilar.

• In July 2017, Merck & Co. Announced the U.S. Launch of RENFLEXIS™ (infliximab-abda), a Biosimilar of Remicade, for All Eligible Indications.

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.